SEC Filing Summary: Nile Therapeutics, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Nile Therapeutics, Inc. on December 6, 2010, reporting events occurring on November 30, 2010. The filing addresses the company's status regarding its listing on The NASDAQ Capital Market. Note: The request metadata references "Capricor Therapeutics, Inc.," but the filing text explicitly identifies the registrant as "Nile Therapeutics, Inc."
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance: the minimum bid price of the Company's common stock remained below $1.00 per share for 30 consecutive business days, triggering a delisting notice.
Material Changes
On November 30, 2010, the Company received a Staff Determination from NASDAQ stating that its common stock would be subject to delisting from The NASDAQ Capital Market. This determination followed the Company's failure to regain compliance with Listing Rule 5550(a)(2) (minimum bid price requirement) by the November 29, 2010 deadline, which was the end of a 180-day compliance period granted after an initial notice on June 1, 2010.
Outlook, Risks, and Management Commentary
- Management Action: The Company intends to request a hearing before the NASDAQ Listing Qualifications Panel to review the Staff Determination.
- Immediate Effect: Requesting a hearing will stay any delisting action and allow the stock to continue trading on NASDAQ until the Panel renders a decision.
- Strategy: At the hearing, the Company plans to present a plan to regain compliance and request additional time.
- Risks: There is no assurance that the Panel will grant the request for continued listing or approve the plan for additional time.
Investor Verification Checklist
- Verify the current status of the NASDAQ Listing Qualifications Panel hearing and the final decision date.
- Confirm the specific plan the Company intends to present to regain compliance with the $1.00 minimum bid price rule.
- Monitor the stock price to determine if it has recovered above the $1.00 threshold.
- Review the attached press release (Exhibit 99.1) for any additional details on the Company's capitalization or financial position not included in the 8-K text.